Nutcracker Therapeutics develops RNA therapeutics using a platform that combines machine learning-driven design, biologic manufacturing, and targeted nanoparticle delivery. The platform enables creation of siRNA and other RNA molecules optimized for specific patients and diseases, with a focus on oncology and immune-mediated disorders. Their proprietary nanocarrier technology delivers RNA payloads intracellularly while minimizing off-target effects. Customers include pharmaceutical partners for co-development. The company targets the RNA therapeutics market, which includes treatments for cancer and autoimmune diseases. Nutcracker has raised $167 million in Series A funding led by ARCH Venture Partners and Takeda Ventures. The founding team includes experts from Harvard and Stanford in computational biology and nanotechnology.